Improvements in Physical Function and Health-Related Quality of Life
In addition to improvements in signs and symptoms of psoriatic arthritis, patients receiving every four week dosing with golimumab also experienced clinically meaningful (increase of at least 0.3) improvement in physical function, as measured by the Health Assessment Questionnaire (HAQ). HAQ assesses the degree of difficulty a patient has in accomplishing tasks in eight functional areas (dressing, arising, eating, walking, hygiene, reaching, gripping and other activities of daily living.) At week 24, patients treated with golimumab 50 mg and 100 mg had a mean improvement of 0.33 and 0.39 score, respectively, as compared to placebo patients worsening by a mean of 0.01 score (P < 0.001). At one year, the mean improvements were 0.49 in patients continuing to receive golimumab 50 mg and 0.45 in patients continuing to receive golimumab 100 mg.
"These findings show golimumab to be promising in improving multiple aspects of psoriatic arthritis, including key areas such as physical function and productivity," said Philip Mease, M.D., Seattle Rheumatology Associates, and Swedish Medical Center, Seattle, and lead study investigator. "The results demonstrate that the effectiveness of golimumab extends beyond the categories of signs and symptoms and improved the lives of patients and those who care for them as measured through this analysis."
Patients in both golimumab groups experienced improvements in HRQOL as measured by the Physical Component Summary (PCS) and Mental Component Summary (MCS) scores of the Short form (SF)-36 questionnaire. SF-36 assesses well- being in patients along eight domains of health status, including physical functioning, pain, vitality, social functioning, psychological functioning, general health perceptions, and role limitations due to physical and emotional problems.
Copyright©2008 PR Newswire.
All rights reserved